Ondine reports significant financial growth
24th Apr 2024 15:09
(Sharecast News) - Ondine Biomedical reported significant growth in a trading update on Wednesday, with revenues doubling to $1.2m in 2023, driven by expanded hospital deployments of 'Steriwave'.
Read moreOndine Biomedical assessing Steriwave with Yorkshire partners
5th Mar 2024 13:50
(Sharecast News) - Ondine Biomedical announced on Tuesday that it is joining forces with the Mid Yorkshire Teaching NHS Trust, Health Innovation Yorkshire and Humber, and the York Health Economics Consortium (YHEC) to assess the potential cost savings associated with using its 'Steriwave' technology.
Read moreOndine raises $3.6m to help commercialise Steriwave
13th Dec 2023 14:43
(Sharecast News) - Life sciences company Ondine Biomedical has successfully raised CAD 4.91m ($3.62m), it announced on Wednesday, bolstering its efforts to commercialise its photodisinfection technology aimed at reducing healthcare-associated infections (HAIs).
Read moreOndine reports strong research findings from Canadian hospitals
23rd Oct 2023 12:15
(Sharecast News) - Ondine Biomedical announced ground-breaking research findings from Vancouver General and University of British Columbia (UBC) Hospitals in British Columbia, Canada, on Monday, after they implemented a universal pre-surgical nasal photodisinfection and chlorhexidine gluconate (CHG) wipes protocol.
Read moreOndine announces expanded Canadian availability of Steriwave
13th Oct 2023 16:15
(Sharecast News) - Life sciences company Ondine Biomedical announced the expansion of the availability of its Steriwave nasal photo disinfection technology on Friday across various hospitals in Canada.
Read moreOndine disinfection tech to be used at another Canadian hospital
7th Aug 2023 10:57
(Sharecast News) - Ondine Biomedical announced on Monday that it is joining forces with Canada's Kelowna General Hospital (KGH) in a pilot targeting the prevention of hospital-acquired infections (HAIs).
Read moreOndine Biomedical reports first-quarter progress
17th Apr 2023 12:06
(Sharecast News) - Life sciences company Ondine Biomedical reported a number of operational highlights in a first-quarter update on Monday, including clinical developments for US market approval, additional clinical data and endorsements, and commercial progress.
Read moreOndine Biomedical upbeat on photodisinfection study
17th Jan 2023 17:30
(Sharecast News) - Ondine Biomedical said on Tuesday that a new study published in the journal Antibiotics found that antimicrobial photodisinfection therapy (aPDT) using its proprietary methylene blue-based photosensitiser in combination with a specific wavelength of light "effectively eradicated" pathogen biofilms commonly associated with periprosthetic joint infections (PJIs).
Read moreOndine reports success in MRSA clinical trial
2nd Dec 2022 12:34
(Sharecast News) - Ondine Biomedical reported full results from its phase two 'BENEFIT-PDT' clinical trial on Friday, which met its primary endpoint of bacterial load reduction after nasal photodisinfection.
Read moreOndine technology 'highly effective' against MRSA isolates
19th Oct 2022 14:00
(Sharecast News) - Canada-based life sciences company Ondine Biomedical announced new research on Wednesday, showing that its photodisinfection technology was "highly effective" against clinical MRSA isolates that exhibited multi-drug resistance.
Read more